Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | Chief Commercial Officer | February 18, 2025 | February 21, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
WEST PHARMACEUTICAL SERVICES INC
Report date February 18, 2025 · Filed February 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,047.329 |
Ending reported balance
After 2025-02-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-18 · Exercise / conversion · Acquired 246.162 · Balance 5,130.508 Row 2 · 2025-02-18 · Tax withholding · Disposed 83.179 · Balance 5,047.329 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $211.00 · Expires 2035-02-18 | Direct | 1,162 |
Reported balance
After 2025-02-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-18 · Grant · Acquired 1,162 · Balance 1,162 F1: This award vests in four equal installments beginning on February 18, 2026. |
| Rst. Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 503 |
Reported balance
After 2025-02-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-18 · Grant · Acquired 503 · Balance 503 F1: This award vests in four equal installments beginning on February 18, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: This award vests in four equal installments beginning on February 18, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2025 Filed Feb 21, 2025 02:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantRst. Stock Unit · Derivative | 503 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-006123 · form4.xml · derivative · entry 4 Reiss-Clark Cindy · CIK 0001916513 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 503 Underlying: Common Stock · 503 shares Expires not disclosed F1 · derivative.exercise_date: This award vests in four equal installments beginning on February 18, 2026. F1 · derivative.expiration_date: This award vests in four equal installments beginning on February 18, 2026. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Option (Right to Buy) · Derivative | 1,162 | $0.00 Strike: $211.00 | $0.00 |
DisclosureSEC source: 0001127602-25-006123 · form4.xml · derivative · entry 3 Reiss-Clark Cindy · CIK 0001916513 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,162 Underlying: Common Stock · 1,162 shares Expires 2035-02-18 F1 · derivative.exercise_date: This award vests in four equal installments beginning on February 18, 2026. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Tax withholdingCommon Stock | 83.179 | $211.00 | $17,550.77 |
DisclosureSEC source: 0001127602-25-006123 · form4.xml · nonDerivative · entry 2 Reiss-Clark Cindy · CIK 0001916513 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,047.329 Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 246.162 | $211.00 | $51,940.18 |
DisclosureSEC source: 0001127602-25-006123 · form4.xml · nonDerivative · entry 1 Reiss-Clark Cindy · CIK 0001916513 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,130.508 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 23:40 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to Buy) · Derivative | 2,411 | $0.00 Strike: $350.18 | $0.00 |
DisclosureSEC source: 0001127602-24-006409 · form4.xml · derivative · entry 2 Reiss-Clark Cindy · CIK 0001916513 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,411 Underlying: Stock Options (Right to Buy) · 2,411 shares Expires 2034-02-20 F2 · derivative.exercise_date: This grant vests in four equal installments beginning on February 20, 2025. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 23:40 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 551 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006409 · form4.xml · nonDerivative · entry 1 Reiss-Clark Cindy · CIK 0001916513 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,884.346 F1 · security: 2021 PSUs (PP20) award vesting net of taxes withheld. Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 23:24 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to buy) · Derivative | 1,112 | $393.34 Strike: $173.22 | $437,394.08 |
DisclosureSEC source: 0001562180-23-006564 · primarydocument.xml · derivative · entry 7 Reiss-Clark Cindy · CIK 0001916513 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,756 Underlying: Common Stock · 1,112 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 18, 2021. Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 23:24 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to buy) · Derivative | 1,588 | $393.34 Strike: $274.29 | $624,623.92 |
DisclosureSEC source: 0001562180-23-006564 · primarydocument.xml · derivative · entry 6 Reiss-Clark Cindy · CIK 0001916513 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,588 Underlying: Common Stock · 1,588 shares Expires 2031-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 23, 2022. Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 23:24 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to buy) · Derivative | 777 | $393.34 Strike: $369.13 | $305,625.18 |
DisclosureSEC source: 0001562180-23-006564 · primarydocument.xml · derivative · entry 5 Reiss-Clark Cindy · CIK 0001916513 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,331 Underlying: Common Stock · 777 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 22, 2023. Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 23:24 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 3,477 | $393.34 | $1,367,643.18 |
DisclosureSEC source: 0001562180-23-006564 · primarydocument.xml · nonDerivative · entry 4 Reiss-Clark Cindy · CIK 0001916513 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,320.1611 Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 23:24 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 777 | $369.13 | $286,814.01 |
DisclosureSEC source: 0001562180-23-006564 · primarydocument.xml · nonDerivative · entry 3 Reiss-Clark Cindy · CIK 0001916513 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,797.1611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 23:24 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 1,588 | $274.29 | $435,572.52 |
DisclosureSEC source: 0001562180-23-006564 · primarydocument.xml · nonDerivative · entry 2 Reiss-Clark Cindy · CIK 0001916513 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,020.1611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 23:24 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 1,112 | $173.22 | $192,620.64 |
DisclosureSEC source: 0001562180-23-006564 · primarydocument.xml · nonDerivative · entry 1 Reiss-Clark Cindy · CIK 0001916513 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,432.1611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:28 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 2,988 | $0.00 Strike: $306.68 | $0.00 |
DisclosureSEC source: 0001562180-23-001796 · primarydocument.xml · derivative · entry 2 Reiss-Clark Cindy · CIK 0001916513 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,988 Underlying: Stock Options (Right to Buy) · 2,988 shares Expires 2033-02-21 F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 21, 2024. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:28 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 970 | $306.68 | $297,479.60 |
DisclosureSEC source: 0001562180-23-001796 · primarydocument.xml · nonDerivative · entry 1 Reiss-Clark Cindy · CIK 0001916513 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,320.1611 F1 · shares: 2020 PSUs (PP19) award vesting net of taxes withheld Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.